Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics

Investors with a lot of money to spend have taken a bearish stance on Iovance Biotherapeutics IOVA.

And retail traders should know.

We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IOVA, it often means somebody knows something is about to happen.

Today, Benzinga's options scanner spotted 19 options trades for Iovance Biotherapeutics.

This isn't normal.

The overall sentiment of these big-money traders is split between 47% bullish and 52%, bearish.

Out of all of the options we uncovered, there was 1 put, for a total amount of $90,900, and 18, calls, for a total amount of $1,219,855.

Predicted Price Range

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $25.0 for Iovance Biotherapeutics over the last 3 months.

Volume & Open Interest Development

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Iovance Biotherapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Iovance Biotherapeutics's whale trades within a strike price range from $10.0 to $25.0 in the last 30 days.

Iovance Biotherapeutics Option Volume And Open Interest Over Last 30 Days

Significant Options Trades Detected:

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Current Position of Iovance Biotherapeutics

• With a volume of 6,858,946, the price of IOVA is up 0.38% at $16.0.
• RSI indicators hint that the underlying stock may be overbought.
• Next earnings are expected to be released in 5 days.

What Analysts Are Saying About Iovance Biotherapeutics

Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $23.0.

• Consistent in their evaluation, an analyst from Chardan Capital keeps a Buy rating on Iovance Biotherapeutics with a target price of $34.
• An analyst from Goldman Sachs persists with their Buy rating on Iovance Biotherapeutics, maintaining a target price of $19.
• Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Iovance Biotherapeutics, targeting a price of $19.
• An analyst from Piper Sandler has decided to maintain their Overweight rating on Iovance Biotherapeutics, which currently sits at a price target of $18.
• An analyst from JMP Securities persists with their Market Outperform rating on Iovance Biotherapeutics, maintaining a target price of $25.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Iovance Biotherapeutics with Benzinga Pro for real-time alerts.